---
title: "Citi Raises CSPC PHARMA  TP to HKD14, Rating Buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296566031.md"
description: "Citi raised its target price for CSPC PHARMAto HKD14, maintaining a Buy rating. The bank cited strong first-half 2026 results, with net profit surging 139% YoY to RMB6.1 billion and revenue up 40% to RMB18.6 billion, driven by licensing income and accelerating finished drug sales growth. Management remains confident in long-term growth supported by new product launches and overseas expansion."
datetime: "2026-08-21T04:06:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296566031.md)
  - [en](https://longbridge.com/en/news/296566031.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296566031.md)
generator: "portal-rs"
---

# Citi Raises CSPC PHARMA  TP to HKD14, Rating Buy

Citi said in a report that CSPC PHARMA (01093.HK) -0.380 (-3.992%) Short selling $478.25M; Ratio 11.096% 's net profit attributable for 1H26 was RMB6.1 billion, up 139% YoY, at the high end of its profit alert range. Revenue rose 40% YoY to RMB18.6 billion, driven by RMB5.9 billion in licensing income. Excluding licensing income, finished drug sales increased 11% YoY to RMB10.2 billion, slightly above the about 10% YoY growth indicated in the profit alert, with growth accelerating from 6% in 1Q26 to about 16% in 2Q26.

Management maintained its guidance for positive growth in finished drug products in 2026 and expressed confidence in the company's growth over the next five years, supported by new product launches, overseas expansion and development milestones in recurring businesses. The broker raised its TP on CSPC PHARMA from HKD11.5 to HKD14, with a Buy rating.(ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-20 16:25.)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)

## Related News & Research

- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [UBS Raises CSPC PHARMA  TP to HKD11.8, Reiterates Buy](https://longbridge.com/en/news/296585459.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**